⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2666838 | 1.00 | — | — | |
| SCHEMBL8267115 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL7262247 | 0.97 | — | — | |
| Sulfuric Acid SCHEMBL11562715 | 0.86 | NOS1 (0.43) | — | |
| Sulfuric Acid SCHEMBL11562717 | 0.86 | NOS1 (0.43) | — | |
| SCHEMBL20865510 | 0.76 | — | — | |
| SCHEMBL9296847 | 0.74 | — | — | |
| SCHEMBL14598241 | 0.74 | — | — | |
| SCHEMBL14868270 | 0.74 | NOS1 (0.43) | — | |
| SCHEMBL14868272 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587176-A2 | POLYGUANIDINE-CONTAINING MEMBRANES AND METHODS OF USING THEREOF | Ohio State Innovation Foundation (US) | 2025-07-23 | — | — | EP | claimed |
| WO-2024059033-A2 | POLYGUANIDINE-CONTAINING MEMBRANES AND METHODS OF USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-03-21 | — | — | WO | claimed |
| EP-2303283-A2 | ANTI-CANCER COMBINATION THERAPY | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2011-04-06 | — | — | EP | claimed |
| US-20110065663-A1 | ANTI-CANCER COMBINATION THERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D | 2011-03-17 | — | — | US | claimed |
| US-20100240682-A1 | PHOPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMATORY DISEASE COMPRISING THYMIDINE PHOSPHORYLASE INHIBITOR AS ACTIVE INGREDIENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-23 | — | — | US | claimed |
| CN-101820914-A | Prophylactic or therapeutic agent for inflammatory disease comprising thymidine phosphorylase inhibitor as active ingredient | TAIHO PHARMACEUTICAL CO LTD | 2010-09-01 | — | — | CN | claimed |
| EP-2204192-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASE COMPRISING THYMIDINE PHOSPHORYLASE INHIBITOR AS ACTIVE INGREDIENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2010-07-07 | — | — | EP | claimed |
| WO-2009138507-A2 | ANTI-CANCER COMBINATION THERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2009-11-19 | — | — | WO | claimed |
| EP-0884051-B1 | CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 2004-12-15 | — | — | EP | claimed |
| EP-0763529-B1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-07-23 | — | — | EP | claimed |
| US-6255314-B1 | Cancerous metastasis inhibitors containing uracil derivatives | TAIHO CHARMACEUTICAL CO., LTD. (JP) | 2001-07-03 | — | — | US | claimed |
| US-6159969-A | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-12 | — | — | US | claimed |
| EP-0884051-A1 | CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1998-12-16 | — | — | EP | claimed |
| EP-0763529-A1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | claimed |
| EP-0536151-B1 | ORTHOSUBSTITUTED BIPHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM | BOOTS CO PLC (GB) | 1994-09-14 | — | — | EP | claimed |
| EP-0385038-B1 | ORTHO-SUBSTITUTED PHENYL AMIDINE AND PHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM | The Boots Company PLC (GB) | 1993-06-02 | — | — | EP | claimed |
| EP-0536151-A1 | ORTHOSUBSTITUTED BIPHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM. | BOOTS CO PLC (GB) | 1993-04-14 | — | — | EP | claimed |
| WO-1992000273-A1 | ORTHOSUBSTITUTED BIPHENYL AMIDINE AND BIPHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM | THE BOOTS COMPANY PLC (GB) | 1992-01-09 | — | — | WO | claimed |
| EP-0385038-A1 | Ortho-substituted phenyl amidine and phenyl guanidine derivatives and antidiabetic or hypoglycaemic agents containing them | The Boots Company PLC (GB) | 1990-09-05 | — | — | EP | claimed |
| EP-4587176-A2 | POLYGUANIDINE-CONTAINING MEMBRANES AND METHODS OF USING THEREOF | Ohio State Innovation Foundation (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025064987-A1 | POLYMERIC SUBSTRATES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2025-03-27 | — | — | WO | disclosed |
| US-12110393-B2 | Crosslinkable organopolysiloxane compositions | WACKER CHEMIE AG (DE) | 2024-10-08 | — | — | US | disclosed |
| WO-2024059033-A2 | POLYGUANIDINE-CONTAINING MEMBRANES AND METHODS OF USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3256442-B1 | SYSTEMS AND PROCESSES FOR POLYACRYLIC ACID PRODUCTION | NOVOMER INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230285338-A9 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | WASHINGTON UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| WO-2023095167-A1 | A PROCESS FOR THE PREPARATION OF INDOLMYCIN AND DERIVATIVES THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2023-06-01 | — | — | WO | disclosed |
| EP-3837304-B1 | CROSSLINKABLE ORGANOYSILOXANE COMPOSITIONS | WACKER CHEMIE AG (DE) | 2021-11-24 | — | — | EP | disclosed |
| WO-2021224494-A1 | NEW TREATMENTS OF VIRAL INFECTIONS | KANCERA AB (SE) | 2021-11-11 | — | — | WO | disclosed |
| US-20210347952-A1 | CROSSLINKABLE ORGANOPOLYSILOXANE COMPOSITIONS | WACKER CHEMIE AG (DE) | 2021-11-11 | — | — | US | disclosed |
| EP-3225627-B1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | UNIV NORTHWEST (CN) | 2021-11-03 | — | — | EP | disclosed |
| WO-2021036975-A1 | PEPTIDE AMIDE COMPOSITION AND PREPARATION METHOD THEREFOR | 四川海思科制药有限公司 | 2021-03-04 | — | — | WO | disclosed |
| EP-3619274-B1 | AQUEOUS DISPERSIONS OF ORGANOSILICON COMPOUNDS | WACKER CHEMIE AG (DE) | 2020-09-09 | — | — | EP | disclosed |
| US-10584244-B2 | Aqueous dispersions of organosilicon compounds | WACKER CHEMIE AG (DE) | 2020-03-10 | — | — | US | disclosed |
| WO-2019195430-A1 | STREPTOCOCCUS MUTANS GLUCOSYL TRANSFERASE INHIBITORS FOR DENTAL CARIES THERAPY | UAB RESEARCH FOUNDATION (US) | 2019-10-10 | — | — | WO | disclosed |
| US-10428083-B2 | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-01 | — | — | US | disclosed |
| EP-3122328-B1 | SILANE CONTAINING RESPECTIVELY AT LEAST TWO ALKOXY GROUPS AND A GUANIDONO OR CARBAMIDE GROUP | EVONIK DEGUSSA GMBH (DE) | 2019-05-01 | — | — | EP | disclosed |
| WO-2019022461-A1 | COMPOUND AND PREPARATION METHOD THEREFOR | 부산대학교 산학협력단 | 2019-01-31 | — | — | WO | disclosed |
| US-10189781-B2 | Onium salt and composition comprising the same | ASAHI KASEI E-MATERIALS CORPORATION (JP) | 2019-01-29 | — | — | US | disclosed |
| US-10077336-B2 | Functionalized highly branched melamine-polyamine polymers | BASF SE (DE) | 2018-09-18 | — | — | US | disclosed |
| US-10017461-B2 | Method of making ligand functionalized substrates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-07-10 | — | — | US | disclosed |
| EP-3256535-B1 | ELASTOMERIC SILICONE EMULSION FOR COATING APPLICATIONS | WACKER CHEMIE AG (DE) | 2018-06-20 | — | — | EP | disclosed |
| US-20180146677-A1 | GUANICIDE COMPOUND AND FUNGICIDE | NIPPON SODA CO., LTD. (JP) | 2018-05-31 | — | — | US | disclosed |
| EP-3256430-B1 | ONE COMPONENT READY-TO-USE TILE GROUT COMPRISING SILYL-TERMINATED POLYMER, SILICONE RESIN, EMULSIFIER, WATER AND AGGREGATE AND METHOD OF GROUTING | WACKER CHEMIE AG (DE) | 2018-05-23 | — | — | EP | disclosed |
| EP-2545123-B1 | POLYAMIDES RESISTANT TO HOT AGEING | BASF SE (DE) | 2018-05-16 | — | — | EP | disclosed |
| US-20180127822-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | PIERCE BIOTECHNOLOGY, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9938243-B2 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20180065981-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-08 | — | — | US | disclosed |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-20180030274-A1 | AQUEOUS DISPERSIONS OF ORGANOSILICON COMPOUNDS | WACKER CHEMIE AG (DE) | 2018-02-01 | — | — | US | disclosed |
| US-9856173-B2 | One component ready-to-use tile grout | WACKER CHEMICAL CORPORATION (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170369448-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-28 | — | — | US | disclosed |
| EP-3256535-A1 | ELASTOMERIC SILICONE EMULSION FOR COATING APPLICATIONS | Wacker Chemie AG (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-9828633-B1 | Modified nucleotides methods and kits | PIERCE BIOTECHNOLOGY, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2017194397-A1 | IMPREGNATING RESIN COMPOSITION, RESIN COATING, LAMINATE CONTAINING SAME, IMPREGNATION PRODUCT, AND METHOD FOR PRODUCING SAME | FRITZ EGGER GMBH & CO. OG (AT) | 2017-11-16 | — | — | WO | disclosed |
| US-9809558-B2 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| US-20170298045-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-10-19 | — | — | US | disclosed |
| US-20170217880-A1 | METHOD OF MAKING LIGAND FUNCTIONALIZED SUBSTRATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2017-08-03 | — | — | US | disclosed |
| EP-2275433-B1 | METASTIN DERIVATIVE AND USE THEREOF | UNIV KYOTO (JP) | 2017-06-07 | — | — | EP | disclosed |
| EP-3038993-B1 | CURABLE ORGANOPOLYSILOXANE COMPOSITIONS | WACKER CHEMIE AG (DE) | 2017-05-31 | — | — | EP | disclosed |
| US-9650470-B2 | Method of making ligand functionalized substrates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-05-16 | — | — | US | disclosed |
| US-9617186-B2 | Curable organopolysiloxane compositions | WACKER CHEMIE AG (DE) | 2017-04-11 | — | — | US | disclosed |
| WO-2016128333-A1 | ELASTOMERIC SILICONE EMULSION FOR COATING APPLICATIONS | WACKER CHEMIE AG (DE) | 2016-08-18 | — | — | WO | disclosed |
| US-20160229749-A1 | ONE COMPONENT READY-TO-USE TILE GROUT | WACKER CHEMICAL CORPORATION | 2016-08-11 | — | — | US | disclosed |
| US-20160229801-A1 | ONIUM SALT AND COMPOSITION COMPRISING THE SAME | ASAHI KASEI E-MATERIALS CORPORATION (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160207832-A1 | CURABLE ORGANOPOLYSILOXANE COMPOSITIONS | WACKER CHEMIE AG (DE) | 2016-07-21 | — | — | US | disclosed |
| US-9328259-B1 | Elastomeric silicone emulsion for coating applications | WACKER CHEMICAL CORPORATION (US) | 2016-05-03 | — | — | US | disclosed |
| EP-2313183-B1 | LIGAND FUNCTIONALIZED SUBSTRATES | 3M INNOVATIVE PROPERTIES CO (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20140364519-A1 | METHOD OF MAKING LIGAND FUNCTIONALIZED SUBSTRATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2014-12-11 | — | — | US | disclosed |
| US-8871210-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-8846203-B2 | Method of making ligand functionalized substrates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8822459-B2 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8778871-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8765909-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2522692-B1 | Ligand monomers and copolymers made therewith | 3M INNOVATIVE PROPERTIES CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20140087445-A1 | METHOD OF MAKING LIGAND FUNCTIONALIZED SUBSTRATES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-27 | — | — | US | disclosed |
| EP-1790639-B1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-8680092-B2 | Nitrogenous heterocyclic compound and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-20140072576-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8652582-B2 | Method of making ligand functionalized substrates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-02-18 | — | — | US | disclosed |
| US-8618122-B2 | Compound having acidic group which may be protected, and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-31 | — | — | US | disclosed |
| US-8614323-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-24 | — | — | US | disclosed |
| US-8592379-B2 | Metastin derivative and use thereof | KYOTO UNIVERSITY (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8586338-B2 | Ligand functionalized substrates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2657235-A1 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-1942108-B1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8519124-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-1756041-B1 | Polycationic compounds and uses thereof | POLYMEDIX INC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-8466221-B2 | Polyamides that resist heat-aging | BASF SE (DE) | 2013-06-18 | — | — | US | disclosed |
| US-8440675-B2 | Potentiator of radiation therapy | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| EP-1961744-B1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-04-17 | — | — | EP | disclosed |
| EP-2042503-B1 | COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-01-30 | — | — | EP | disclosed |
| US-8361968-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-2545123-A1 | POLYAMIDES RESISTANT TO HOT AGEING | BASF SE (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-20120328627-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-12-27 | — | — | US | disclosed |
| US-8318931-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| CN-101484443-B | Potentiator of radiation therapy | TAIHO PHARMACEUTICAL CO LTD | 2012-11-21 | — | — | CN | disclosed |
| EP-2522692-A1 | Ligand monomers and copolymers made therewith | 3M Innovative Properties Company (US) | 2012-11-14 | — | — | EP | disclosed |
| CN-101820880-B | Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient | TAIHO PHARMACEUTICAL CO LTD | 2012-11-14 | — | — | CN | disclosed |
| EP-2513201-A1 | FUNCTIONALIZED HIGHLY BRANCHED MELAMINE-POLYAMINE POLYMERS | BASF SE (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-8293896-B2 | — | — | 2012-10-23 | — | — | US | disclosed |
| US-20120252987-A1 | FUNCTIONALIZED HIGHLY BRANCHED MELAMINE-POLYAMINE POLYMERS | BASF SE (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120207765-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8188105-B2 | Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| EP-2036903-B1 | POTENTIATOR OF RADIATION THERAPY | TAIHO PHARMACEUTICAL CO LTD (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-8168783-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-8148381-B2 | Potentiator of radiation therapy | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20120015868-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120010165-A1 | POTENTIATOR OF RADIATION THERAPY | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| EP-2380872-A1 | Polycationic compounds and uses thereof | Polymedix, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2011128437-A1 | HIGHLY BRANCHED AMINE POLYMERS AND AMINE OLIGOMERS AS CORROSION INHIBITOR | BASF SE (DE) | 2011-10-20 | — | — | WO | disclosed |
| US-20110257321-A1 | HIGHLY BRANCHED POLYAMINES AND OLIGOAMINES AS CORROSION INHIBITORS | BASF SE (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110224347-A1 | POLYAMIDES THAT RESIST HEAT-AGING | BASF SE (DE) | 2011-09-15 | — | — | US | disclosed |
| WO-2011110508-A1 | POLYAMIDES RESISTANT TO HOT AGEING | BASF SE (DE) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011095428-A1 | HEXAORGANO GUANIDINIUM ORGANOCARBONATES, THE PRODUCTION OF SAME AND THE USE THEREOF | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2011-08-11 | — | — | WO | disclosed |
| US-20110184078-A1 | Ligand Functionalized Substrates | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2011-07-28 | — | — | US | disclosed |
| WO-2011073246-A1 | FUNCTIONALIZED HIGHLY BRANCHED MELAMINE-POLYAMINE POLYMERS | BASF SE (DE) | 2011-06-23 | — | — | WO | disclosed |
| US-20110142856-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-7951816-B2 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| EP-2313183-A1 | LIGAND FUNCTIONALIZED SUBSTRATES | 3M Innovative Properties Company (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-2303283-A2 | ANTI-CANCER COMBINATION THERAPY | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2011-04-06 | — | — | EP | disclosed |
| US-20110065663-A1 | ANTI-CANCER COMBINATION THERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D | 2011-03-17 | — | — | US | disclosed |
| US-20110059888-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-10 | — | — | US | disclosed |
| EP-2285861-A2 | HYPERBRANCHED POLYMERS AND OLIGOMERS COMPRISING TERMINAL AMINO GROUPS AS CURING AGENTS FOR EPOXY RESINS | BASF SE (DE) | 2011-02-23 | — | — | EP | disclosed |
| US-20110039786-A1 | METASTIN DERIVATIVE AND USE THEREOF | KYOTO UNIVERSITY (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110033633-A1 | METHOD OF MAKING LIGAND FUNCTIONALIZED SUBSTRATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2011-02-10 | — | — | US | disclosed |
| US-20110028603-A1 | HYPERBRANCHED POLYMERS AND OLIGOMERS COMPRISING TERMINAL AMINO GROUPS AS CURING AGENTS FOR EPOXY RESINS | BASF SE (DE) | 2011-02-03 | — | — | US | disclosed |
| EP-2275433-A1 | METASTIN DERIVATIVE AND USE THEREOF | Kyoto University (JP) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009146321-A9 | LIGAND FUNCTIONALIZED SUBSTRATES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100240682-A1 | PHOPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMATORY DISEASE COMPRISING THYMIDINE PHOSPHORYLASE INHIBITOR AS ACTIVE INGREDIENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| US-20100222372-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE COMPRISING URACIL DERIVATIVE AS ACTIVE INGREDIENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-02 | — | — | US | disclosed |
| CN-101820880-A | Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient | TAIHO PHARMACEUTICAL CO LTD | 2010-09-01 | — | — | CN | disclosed |
| CN-101820914-A | Prophylactic or therapeutic agent for inflammatory disease comprising thymidine phosphorylase inhibitor as active ingredient | TAIHO PHARMACEUTICAL CO LTD | 2010-09-01 | — | — | CN | disclosed |
| US-7786083-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| EP-2204192-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASE COMPRISING THYMIDINE PHOSPHORYLASE INHIBITOR AS ACTIVE INGREDIENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2010-07-07 | — | — | EP | disclosed |
| EP-2204175-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE COMPRISING URACIL DERIVATIVE AS ACTIVE INGREDIENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090318365-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090298765-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-03 | — | — | US | disclosed |
| WO-2009146321-A1 | LIGAND FUNCTIONALIZED SUBSTRATES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-12-03 | — | — | WO | disclosed |
| US-7625869-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-01 | — | — | US | disclosed |
| WO-2009138507-A2 | ANTI-CANCER COMBINATION THERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2009-11-19 | — | — | WO | disclosed |
| US-20090286755-A1 | POTENTIATOR OF RADIATION THERAPY | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2113513-A2 | Metastin derivatives and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | disclosed |
| WO-2009124998-A2 | HYPERBRANCHED POLYMERS AND OLIGOMERS COMPRISING TERMINAL AMINO GROUPS AS CURING AGENTS FOR EPOXY RESINS | BASF SE (DE) | 2009-10-15 | — | — | WO | disclosed |
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090215700-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-27 | — | — | US | disclosed |
| US-20090192182-A1 | COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF | ONO PHARMACEUTICAL CO.,LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| CN-101484443-A | Potentiator of radiation therapy | TAIHO PHARMACEUTICAL CO LTD (JP) | 2009-07-15 | — | — | CN | disclosed |
| WO-2009080787-A1 | HYPERBRANCHED UREA-MELAMINE POLYMERS | BASF SE (DE) | 2009-07-02 | — | — | WO | disclosed |
| US-20090169567-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090118279-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
| EP-2042503-A1 | COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-2036903-A1 | POTENTIATOR OF RADIATION THERAPY | Taiho Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1961744-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
| EP-1942108-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-7351743-B1 | Therapeutic guanidines | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-10 | — | — | US | disclosed |
| US-20070265348-A1 | N-(4-sec-butylphenyl)-N-benzylguanidine; modulate, particularly inhibit, the release of neurotransmitter such as glutamate; neurodegenerative disease: Parkinson's, Huntington's, Alzheimer's diseases, Amyotrophic Lateral Sclerosis, Down's Syndrome, epilepsy, atrophy, HIV | SCION PHARMACEUTICALS, INC, A DELAWARE CORPORATION | 2007-11-15 | — | — | US | disclosed |
| EP-1852432-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1790639-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1758932-A2 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20060241051-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-26 | — | — | US | disclosed |
| US-7112337-B2 | Liposome composition for delivery of nucleic acid | ALZA CORPORATION (US) | 2006-09-26 | — | — | US | disclosed |
| WO-2006001499-A2 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | WO | disclosed |
| EP-1577323-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1230925-B1 | USE OF A TRIFLURIDINE DERIVATIVE ALONE OR COMBINED WITH A THYMIDINE PHOSPHORYLASE INHIBITOR FOR THE TREATMENT OF HIV | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-0884051-B1 | CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 2004-12-15 | — | — | EP | disclosed |
| EP-1465599-A1 | LIPOSOME COMPOSITION FOR DELIVERY OF NUCLEIC ACID | ALZA Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040197390-A1 | Neutral-cationic lipid for systemic delivery of factor VIII gene | HUANG SHI-KUN (US) | 2004-10-07 | — | — | US | disclosed |
| US-6787569-B1 | INHIBITORS OF NEUROTRANSMITTER (E.G., GLUTAMATE) RELEASE FROM ISCHEMIC NEURONAL CELLS; N,N-DISUBSTITUTED GUANIDINES; NEUROLOGICAL CONDITIONS SUCH AS EPILEPSY, NEURODEGENERATIVE CONDITIONS AND/OR NERVE CELL DEATH FROM STROKE OR HEART ATTACK | CAMBRIDGE NEUROSCIENCE, INC. | 2004-09-07 | — | — | US | disclosed |
| US-20040166150-A1 | Neutral-cationic lipid for systemic delivery of Factor VIII gene | HUANG SHI-KUN (US) | 2004-08-26 | — | — | US | disclosed |
| EP-0763529-B1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-07-23 | — | — | EP | disclosed |
| US-6596720-B1 | Potentiating an anti-HIV activity of trifluridine and derivatives in thereof in a mammal, including human, comprising administering to said mammal, including human, an effective amount of a thymidine phosphorylase inhibitor and | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| WO-2003053409-A1 | LIPOSOME COMPOSITION FOR DELIVERY OF NUCLEIC ACID | ALZA CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
| US-6525200-B1 | Fused pyridine and cyclohexane rings and having optionally other substituents; complexing and quantitating such as urea or guanidine | ROCHE DIAGNOSTICS CORPORATION | 2003-02-25 | — | — | US | disclosed |
| US-20030031704-A1 | Liposome mixture of a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiological pH, and a lipid joined to a hydrophilic polymer by an aromatic disulfide linkage, associated with a nucleic | ALZA CORPORATION | 2003-02-13 | — | — | US | disclosed |
| EP-1271234-A2 | Method of forming images | FUJI PHOTO FILM CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002096390-A1 | NEUTRAL-CATIONIC LIPID FOR SYSTEMIC DELIVERY OF FACTOR VIII GENE | ALZA CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1230925-A1 | ANTI-HIV COMPOSITIONS | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2002-08-14 | — | — | EP | disclosed |
| WO-2002014465-A2 | MULTICYCLIC AROMATIC COMPOUNDS AND USES THEREOF | ROCHE DIAGNOSTICS CORPORATION (US) | 2002-02-21 | — | — | WO | disclosed |
| CN-1320123-A | Disubstituted maleimide compounds and medicinal utilization thereof | JAPAN TOBACCO INC (JP) | 2001-10-31 | — | — | CN | disclosed |
| US-6294535-B1 | TREATING CANCER, WHICH COMPRISES ADMINISTERING TO A PATIENT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF A URACIL DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2001-09-25 | — | — | US | disclosed |
| EP-1120414-A1 | DISUBSTITUTED MALEIMIDE COMPOUNDS AND MEDICINAL UTILIZATION THEREOF | JAPAN TOBACCO INC. (JP) | 2001-08-01 | — | — | EP | disclosed |
| US-6255314-B1 | Cancerous metastasis inhibitors containing uracil derivatives | TAIHO CHARMACEUTICAL CO., LTD. (JP) | 2001-07-03 | — | — | US | disclosed |
| US-6159969-A | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-12 | — | — | US | disclosed |
| EP-0685234-B1 | DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER | NIPPON SHINYAKU CO LTD (JP) | 2000-05-10 | — | — | EP | disclosed |
| US-6020317-A | Glycerol derivative, device and pharmaceutical composition | NIPPON SHINYAKU CO. LTD. (JP) | 2000-02-01 | — | — | US | disclosed |
| EP-0685457-B1 | GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION | NIPPON SHINYAKU CO LTD (JP) | 1999-12-15 | — | — | EP | disclosed |
| EP-0918460-A1 | METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1999002145-A1 | COMBINATION DRUG THERAPIES COMPRISING AMINOGLYCOSIDE ANTIBIOTICS AND N,N'-DISUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-01-21 | — | — | WO | disclosed |
| EP-0884051-A1 | CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1998-12-16 | — | — | EP | disclosed |
| US-5744475-A | 4-N-HET-METHYLURACIL DERIVATIVES; THYMIDINE PHOSPHORYLASE INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1998-04-28 | — | — | US | disclosed |
| WO-1998004131-A1 | METHODS OF TREATMENT OF EYE TRAUMA AND DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
| US-5705188-A | LIPID MIXTURE, ANTITUMOR AGENTS | NIPPON SHINYAKU COMPANY, LTD. (JP) | 1998-01-06 | — | — | US | disclosed |
| EP-0763529-A1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |
| EP-0762201-A1 | Method of forming images | FUJI PHOTO FILM CO., LTD (JP) | 1997-03-12 | — | — | EP | disclosed |
| US-5604228-A | ADMINISTERING AS ANTIPSYCHOTIC OR ANTIHALLUCINOGENIC AGENTS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1997-02-18 | — | — | US | disclosed |
| US-5574070-A | Substituted guanidines having high binding to the sigma receptor and the use thereof | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1996017612-A1 | USE OF SUBSTITUTED PHENYLAMIDINE AND PHENYLGUANIDINE COMPOUNDS FOR THE TREATMENT OF CEREBRAL AND CARDIAC ISCHAEMIA, CONVULSION AND SICKLE CELL ANAEMIA | KNOLL AKTIENGESELLSCHAFT (DE) | 1996-06-13 | — | — | WO | disclosed |
| US-5510361-A | ANALGESICS | THE PROCTER & GAMBLE COMPANY (US) | 1996-04-23 | — | — | US | disclosed |
| US-5502255-A | HYPOTENSIVE AGENTS, PSYCHOLOGICAL DISORDERS AND AS ANTIDEPRESSANTS | STATE OF OREGON ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1996-03-26 | — | — | US | disclosed |
| US-5478863-A | Hypotensive agents, drugs for treating psychological disorders | STATE OF OREGON, OREGON HEALTH SCIENCES UNIVERSITY OF OREGON (US) | 1995-12-26 | — | — | US | disclosed |
| EP-0685457-A1 | GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-12-06 | — | — | EP | disclosed |
| EP-0685234-A1 | DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-12-06 | — | — | EP | disclosed |
| US-5385946-A | Method for treating hypertension with disubstituted granidine compounds | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1995-01-31 | — | — | US | disclosed |
| US-5373008-A | Phenylamidine and phenylguanidine derivatives and their use as anti-diabetic agents | THE BOOTS COMPANT PLC. (GB) | 1994-12-13 | — | — | US | disclosed |
| EP-0536151-B1 | ORTHOSUBSTITUTED BIPHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM | BOOTS CO PLC (GB) | 1994-09-14 | — | — | EP | disclosed |
| EP-0473671-B1 | USE OF SIGMA-RECEPTORS LIGANDS FOR THE MANUFACTURE OF AN ANXIOLYTIC AGENT | OREGON STATE (US) | 1994-08-24 | — | — | EP | disclosed |
| US-5312840-A | Substituted guanidines having high binding to the sigma receptor and the use thereof | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION (US) | 1994-05-17 | — | — | US | disclosed |
| EP-0532642-A4 | — | — | 1994-04-27 | — | — | EP | disclosed |
| US-5302720-A | Biphenyl-substituted guanidine derivatives useful as hypoglycaemic agents | THE BOOTS COMPANY (GB) | 1994-04-12 | — | — | US | disclosed |
| US-5223498-A | Hypoglycemic agents | THE BOOTS COMPANY PLC (GB) | 1993-06-29 | — | — | US | disclosed |
| EP-0385038-B1 | ORTHO-SUBSTITUTED PHENYL AMIDINE AND PHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM | The Boots Company PLC (GB) | 1993-06-02 | — | — | EP | disclosed |
| EP-0532642-A1 | SUBSTITUTED GUANIDINES HAVING HIGH BINDING TO THE SIGMA RECEPTOR AND THE USE THEREOF | STATE OF OREGON, acting through OREGON STATE BOARD OF HIGHER EDUCATION, acting for OREGON HEALTH SC. UNIV. AND UNIV. OF OREGON (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0473671-A4 | METHODS FOR TREATING ANXIETY WITH SIGMA RECEPTOR LIGANDS | — | 1992-04-01 | — | — | EP | disclosed |
| EP-0473671-A1 | USE OF SIGMA-RECEPTORS LIGANDS FOR THE MANUFACTURE OF AN ANXIOLYTIC AGENT. | OREGON STATE (US) | 1992-03-11 | — | — | EP | disclosed |
| WO-1992000273-A1 | ORTHOSUBSTITUTED BIPHENYL AMIDINE AND BIPHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM | THE BOOTS COMPANY PLC (GB) | 1992-01-09 | — | — | WO | disclosed |
| WO-1991018868-A1 | SUBSTITUTED GUANIDINES HAVING HIGH BINDING TO THE SIGMA RECEPTOR AND THE USE THEREOF | STATE OF OREGON, acting by and through the OREGON STATE BOARD OF HIGHER EDUCATION, acting for and onbehalf of the OREGON HEALTH SCIENCES UNIVERSITY (US) | 1991-12-12 | — | — | WO | disclosed |
| WO-1990014067-A2 | METHODS FOR TREATING ANXIETY WITH SIGMA RECEPTOR LIGANDS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1990-11-29 | — | — | WO | disclosed |
| EP-0385038-A1 | Ortho-substituted phenyl amidine and phenyl guanidine derivatives and antidiabetic or hypoglycaemic agents containing them | The Boots Company PLC (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0228192-A2 | Renin-inhibitory oligopeptides, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1987-07-08 | — | — | EP | disclosed |
| EP-0085913-B1 | REACTIVE POLYMERS CONTAINING CARBOXYLIC GROUPS, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS CURING AGENTS IN POWDER LACQUERS | BAYER AG (DE) | 1987-05-13 | — | — | EP | disclosed |
| US-4602071-A | Process for the production of oligourethanes containing mercapto groups and their use as binders for coating and sealing compositions hardenable by oxidation and as additives for epoxide resins | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-22 | — | — | US | disclosed |
| US-4524787-A | HYDROLYSIS OF GUANIDINE OR ACETAMIDINE | JOHNSON PRODUCTS CO., INC. (US) | 1985-06-25 | — | — | US | disclosed |
| EP-0066167-B1 | PROCESS FOR THE PREPARATION OF OLIGOURETHANES CONTAINING MERCAPTO GROUPS, THEIR USE AS BINDERS FOR COATING AND CAULKING MASSES THAT SET BY OXIDATION, OR AS AN ADDITIVE FOR EPOXY RESINS | BAYER AG (DE) | 1985-03-27 | — | — | EP | disclosed |
| EP-0051787-B1 | AMIDINES AND AMIDINE/ISOCYANATE ADDUCTS, METHODS OF PREPARING THEM AND THEIR USE AS CATALYSTS IN CURING EPOXY RESINS | BAYER AG (DE) | 1984-12-19 | — | — | EP | disclosed |
| US-4465826-A | Catalyst systems containing an organic disulfide carboxylates and/or organic complex compounds of metals, and basic amines for the oxidative hardening of plastics precursors containing mercapto groups | BAYER AKTIENGESELLSCHAFT (DE) | 1984-08-14 | — | — | US | disclosed |
| US-4455426-A | CATALYST FOR HARDENING EPOXY RESINS | BAYER AKTIENGESELLSCHAFT (DE) | 1984-06-19 | — | — | US | disclosed |
| US-4455425-A | EPOXY RESINS, CURING AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1984-06-19 | — | — | US | disclosed |
| EP-0100901-A2 | Hair relaxer | Johnson Products Co., Inc. (US) | 1984-02-22 | — | — | EP | disclosed |
| US-4424313-A | ORGANO-NITROGEN SALTS | BAYER AKTIENGESELLSCHAFT (DE) | 1984-01-03 | — | — | US | disclosed |
| US-4424353-A | INTERMEDIATES FOR ISOCYANATE ADDUCTS, EPOXY RESIN CURING AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1984-01-03 | — | — | US | disclosed |
| EP-0085913-A1 | Reactive polymers containing carboxylic groups, process for their production and their use as curing agents in powder lacquers | BAYER AG (DE) | 1983-08-17 | — | — | EP | disclosed |
| EP-0066152-A1 | Application of catalytic systems containing organic sulphur compounds, carboxylates and/or organic complex compounds of metals, as well as organic bases for the oxidative cure of plastics precursors possessing mercapto groups | BAYER AG (DE) | 1982-12-08 | — | — | EP | disclosed |
| EP-0066167-A1 | Process for the preparation of oligourethanes containing mercapto groups, their use as binders for coating and caulking masses that set by oxidation, or as an additive for epoxy resins | BAYER AG (DE) | 1982-12-08 | — | — | EP | disclosed |
| EP-0051787-A2 | Amidines and amidine/isocyanate adducts, methods of preparing them and their use as catalysts in curing epoxy resins | BAYER AG (DE) | 1982-05-19 | — | — | EP | disclosed |
| EP-0051787-A2 | Amidines and amidine/isocyanate adducts, methods of preparing them and their use as catalysts in curing epoxy resins | BAYER AG (DE) | 1982-05-19 | — | — | EP | disclosed |